Is peptide receptor radionuclide therapy an option after liver transplantation in progressive metastatic neuroendocrine tumors?

被引：0
|
作者：
Kulkarni, Harshad [1 ]
Kaemmerer, Daniel [2 ]
Hoersch, Dieter [3 ]
Hommann, Merten [2 ]
Baum, Richard [1 ]
机构：
[1] Zent Klin, Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Zent Klin, Gen & Visceral Surg, Bad Berka, Germany
[3] Zent Klin, Internal Med Gastroenterol & Endocrinol, Bad Berka, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1177
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Metastatic Neuroendocrine Tumors: How Effective and Safe Are They?
    Liotsou, T.
    Stefanoyiannis, A. P.
    Chatziioannou, S. N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S725 - S726
  • [22] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs): A United States Experience
    Katona, Bryson
    Riff, Brian
    Soulen, Michael
    Pryma, Daniel
    Bennett, Bonita
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina
    Metz, David
    PANCREAS, 2017, 46 (03) : 439 - 439
  • [23] Peptide receptor radionuclide therapy (PRRNT) in metastatic neuroendocrine tumors (NETs) arising from the kidney
    Prasad, Vikas
    Kulkarni, Harshad
    Zachert, Carolin
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [24] Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors
    Gujarathi, Rushabh
    Tobias, Joseph
    Abou Azar, Sara
    Keutgen, Xavier M.
    Liao, Chih-Yi
    CANCERS, 2024, 16 (17)
  • [25] Surgery and peptide receptor radionuclide therapy: An effective multimodal approach for metastatic neuroendocrine tumors.
    Frilling, Andreja
    Clift, Ashley
    Al-Nahhas, Adil
    Baum, Richard P.
    Kaemmerer, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Peptide receptor radionuclide therapy versus capecitabine/ temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors
    Gujarathi, R.
    Tobias, J.
    Azar, S. A.
    Keutgen, X.
    Liao, C-Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S94 - S94
  • [27] Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1,000 Patients from a Single Center
    Baum, R. P.
    Kulkarni, H.
    Zachert, C.
    Kaemmerer, D.
    Petrovitch, A.
    Niepsch, K.
    Hommann, M.
    Hoersch, D.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 282 - 282
  • [28] Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors
    Alsadik, S. R.
    Gnanasegaran, G.
    Chen, L.
    Toumpanakis, C.
    Caplin, M.
    Navalkissoor, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 171 - 171
  • [29] AN ALTERNATIVE THERAPY OPTION IN METASTATIC THYROID CANCER: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY
    Cinkir, Havva Yesil
    Elboga, Umut
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2020, 83 (04): : 339 - 344
  • [30] Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Baum, Richard P.
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (03) : 241 - 243
12345